Abstract：
OBJECTIVE: To assess thrombotic risk with PAI-1 levels in patients with COVID-19, to evaluate PAI-1 differences between hyperglycemic and/or Type 2 Diabetes Mellitus (T2DM) versus non-hyperglycemic patients, and to analyze the association of plasminogen activator inhibitor-1 (PAI-1) with hyperglycemia and T2DM.
METHODS: A cross-sectional study carried out in 181 patients hospitalized for COVID-19. Two groups were formed: the patients with hyperglycemia at admission and/or previously diagnosed T2DM group and the non-hyperglycemic group. Fibrinolysis was assessed by measuring PAI-1 levels by ELISA.
RESULTS: The mean age was 59.4±16.1 years; 55.8% were male 54.1% of patients presented obesity, 38.1% had pre-existing T2DM and 50.8% had admission hyperglycemia and/or pre-existing T2DM. The patients with admission hyperglycemia and/or preexisting T2DM had higher PAI-1 compared with non-hyperglycemic patients [197.5 (128.8-315.9) vs 158.1 (113.4-201.4) ng/mL; p=0.031]. The glucose levels showed a positive correlation with PAI-1 levels (r=0.284, p=0.041). A multivariate logistic regression analysis showed association of PAI-1 level and hyperglycemia and pre-existing T2DM with severity of COVID-19.
CONCLUSIONS: Patients hospitalized for COVID-19 infection with preexisting T2DM or hyperglycemia detected during their hospitalization presented a greater increase in PAI-1 levels, which suggests that hyperglycemia contributes directly to the hypercoagulable state and probably a worse outcome from the patients.
METHODS: A cross-sectional study carried out in 181 patients hospitalized for COVID-19. Two groups were formed: the patients with hyperglycemia at admission and/or previously diagnosed T2DM group and the non-hyperglycemic group. Fibrinolysis was assessed by measuring PAI-1 levels by ELISA.
RESULTS: The mean age was 59.4±16.1 years; 55.8% were male 54.1% of patients presented obesity, 38.1% had pre-existing T2DM and 50.8% had admission hyperglycemia and/or pre-existing T2DM. The patients with admission hyperglycemia and/or preexisting T2DM had higher PAI-1 compared with non-hyperglycemic patients [197.5 (128.8-315.9) vs 158.1 (113.4-201.4) ng/mL; p=0.031]. The glucose levels showed a positive correlation with PAI-1 levels (r=0.284, p=0.041). A multivariate logistic regression analysis showed association of PAI-1 level and hyperglycemia and pre-existing T2DM with severity of COVID-19.
CONCLUSIONS: Patients hospitalized for COVID-19 infection with preexisting T2DM or hyperglycemia detected during their hospitalization presented a greater increase in PAI-1 levels, which suggests that hyperglycemia contributes directly to the hypercoagulable state and probably a worse outcome from the patients.
摘要：
目的：评估COVID-19患者PAI-1水平的血栓形成风险，评估高血糖和/或2型糖尿病（T2DM）与非高血糖患者之间PAI-1的差异，分析纤溶酶原激活物抑制因子-1(PAI-1)与高血糖及T2DM的关系。
方法：对181例因COVID-19而住院的患者进行了一项横断面研究。分为两组：入院时高血糖患者和/或先前诊断为T2DM组和非高血糖组。通过ELISA测量PAI-1水平来评估纤维蛋白溶解。
结果：平均年龄为59.4±16.1岁；55.8%为男性，54.1%为肥胖患者，38.1%患有预先存在的T2DM，50.8%患有入院高血糖和/或预先存在的T2DM。入院高血糖和/或先前存在T2DM的患者的PAI-1水平高于非高血糖患者[197.5(128.8-315.9)比158.1(113.4-201.4)ng/mL;p=0.031]。血糖水平与PAI-1水平呈正相关(r=0.284,p=0.041)。多因素logistic回归分析显示PAI-1水平、高血糖和2型糖尿病与COVID-19严重程度相关。
结论：因COVID-19感染而住院的患者在住院期间检测到已有T2DM或高血糖，其PAI-1水平升高更大，这表明高血糖直接导致高凝状态，并可能导致患者的不良结局。
方法：对181例因COVID-19而住院的患者进行了一项横断面研究。分为两组：入院时高血糖患者和/或先前诊断为T2DM组和非高血糖组。通过ELISA测量PAI-1水平来评估纤维蛋白溶解。
结果：平均年龄为59.4±16.1岁；55.8%为男性，54.1%为肥胖患者，38.1%患有预先存在的T2DM，50.8%患有入院高血糖和/或预先存在的T2DM。入院高血糖和/或先前存在T2DM的患者的PAI-1水平高于非高血糖患者[197.5(128.8-315.9)比158.1(113.4-201.4)ng/mL;p=0.031]。血糖水平与PAI-1水平呈正相关(r=0.284,p=0.041)。多因素logistic回归分析显示PAI-1水平、高血糖和2型糖尿病与COVID-19严重程度相关。
结论：因COVID-19感染而住院的患者在住院期间检测到已有T2DM或高血糖，其PAI-1水平升高更大，这表明高血糖直接导致高凝状态，并可能导致患者的不良结局。
